Hints and tips:
...On Monday, it entered into a deferred prosecution agreement with the US Department of Justice over a criminal price-fixing scandal....
...Teva is trying to transcend its history, which includes the highly leveraged acquisition of generics rival Actavis for $40bn in 2016. Needless to say, it wants to pivot into drug development....
...Auden McKenzie hiked prices by over 10,000 per cent and paid off would-be competitors, a practice continued by Actavis UK when it took over sales of the tablets in 2015, the regulator said....
...A planned takeover of Allergan by US drugmaker Pfizer in 2015 fell through a year later when Barack Obama’s administration took steps to scupper a deal which was designed to help Pfizer escape paying US...
...It was once a Wall Street darling, executing an inversion deal with Actavis and other aggressive acquisitions. As its growth prospects slowed, investors grew restless....
...That transaction, which was worth $160bn, would have allowed Pfizer to redomicile to Ireland by merging into Allergan and allow the US drugmaker to escape US taxes....
...The firm’s original investment in Allergan was a money-spinner, reaping gains of $2.3bn before the company agreed a sale to Actavis....
....; Teva Pharmaceuticals USA; Actavis Holdco U.S., Inc.; Actavis Pharma, Inc.; Ascend Laboratories, LLC; Apotex Corp.; Dr....
...Actavis to keep prices artificially high....
...Last year US group Pfizer was fined a record £84m in the UK for charging excessive prices for a drug to treat epilepsy while GlaxoSmithKline and other generics manufacturers were fined £45m over the sale...
...However shares in the $84bn US-listed Irish pharma group were held back by the sharp-off in Teva....
...Actavis was sold last year by Allergan of the US to Israel’s Teva for $40.5bn....
...The relevant SEC filings were made by Allergan, Inc. prior to its acquisition by Actavis plc....
...The court also gave a partial victory to drugmakers Actavis and Par Pharmaceutical, which had lost a patent battle with Indivior....
...Teva, the Israeli maker of generic drugs, bought Actavis Generics from the US’s Allergan for $40.5bn....
...The group has ongoing patent disputes with Mylan, Actavis, Par, Sandoz, Alvogen and Rhodes Pharmaceuticals, all of which are attempting to launch their own opioid addiction treatments....
...Worse for Teva, it doubled down on generics by paying roughly $40bn for Allergan’s Actavis unit — just before prices started to crumble and after some investors warned against the deal....
...US drugmaker Pfizer plans to continue a legal battle with rival Actavis over the way its blockbuster drug Lyrica is sold in the UK after the Court of Appeal on Thursday rejected a claim of patent infringement...
...Teva’s share price has slumped more than 40 per cent over the past year as it digested its landmark $40.5bn acquisition of Actavis Generics and faced a string of problems, including patent challenges to...
...It is also facing an appeal in a patent battle against Actavis and Par Pharmaceutical....
...The CMA also accused Actavis of charging the NHS “excessive” prices for hydrocortisone tablets after prices rose 12,000 per cent....
...The country’s competition authorities alleged generic companies Concordia and Actavis had fixed the UK market for hydrocortisone tablets....
...In 2013 Ireland-based Warner Chilcott bought US-based Actavis, then in 2015, Actavis bought US-based Allergan....
International Edition